Posted by Site Administrator on March 1, 2013
Because of the relentless effects of ALS, a diverse group of ALS voices — patients, families, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, clinical trials and standards of care.
Categories: Clinical Trials, Research News, Treatments
| 
Tags: a diverse group of ALS voices — patients, ALS, ALS clinical trials, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS survivor Robert Anderson, ALS treatments, amyotrophic lateral sclerosis, Because of the relentless effects of ALS, Bob Stehlin, clinical trials and standards of care., Dr. Jonathan Glass, families, fast-track trials ALS, FDA, FDA ALS, Food and Drug Administration, Lou Gehrig's disease, MDA Senior Vice President of Advocacy Annie Kennedy, MDA/ALS Center of Hope in Philadelphia, MDA/ALS Clinic at Methodist Neurological Institute in Houston, Muscular Dystrophy Association MDA, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Sara M. Feldman, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stan Appel, Steven M. Derks
| 
No comments
Posted by Site Administrator on January 15, 2013
“Some may look at recent failures and be discouraged,” wrote Richard Bedlack of the Duke ALS Clinic in Durham, North Carolina, in an e-mail to Alzforum. Thanks to advances in genetics and biomarkers, and a list of potential target pathways, “I think this is a time of unprecedented hope and excitement in ALS research”
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS clinical trials, ALS community, ALS Functional Rating Scale (ALSFRS), ALS Phase 3 studies, ALS research, ALS research funding, ALS sodium chlorite, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Angela Genge, Annual Symposium on Amyotrophic Lateral Sclerosis/Motor Neuron Disease, antisense oligonucleotide therapy ALS, astrocyte excitatory amino acid transporter 2, Benjamin Brooks, Biogen Idec, biomarkers ALS, Bob Stehlin, ceftriaxone, CK-2017357, cytochrome P450 1A2, Cytokinetics, dexpramipexole, Dr. Timothy Miller, Duke ALS Clinic Durham, Emory University Atlanta, Evan Snyder, FDA, fingolimod, Food and Drug Administration, Forbes Norris MDA/ALS Research Center, genetics ALS, Gilenya, immune-system drugs ALS, Inc., ISIS 333611, Isis Pharmaceuticals, Jeremy Shefner, Jonathan Glass, Les Turner ALS Foundation, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz, mitochondrial modulator, Montréal Neurological Institute and Hospital, mutant human superoxide dismutase 1, mutant superoxide dismutase 1, Neil Cashman, Neuralstem Inc, Neuraltus, North Carolina, Northeast ALS Consortium, Novartis, NP001, olesoxime, oligonucleotide, oligonucleotide ALS, oligonucleotide via intrathecal infusion, PALS, Phase III trial ALS, Pitié-Salpêtrière Hospital, RASCALS Foundation, Richard Bedlack, riluzole, Robert A. Stehlin Campaign for ALS, Robert Brown, Robert Miller, Sanford-Burnham Medical Research Institute, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, State University of New York Upstate Medical University, stem cell trial ALS, Steven Perrin, Susanna Benn, synaptic glutamate, target pathways ALS, Tim Miller, Timothée Lenglet, Tirasemtiv, troponin ALS, University of British Columbia, University of Massachusetts Medical School Worcester, University of North Carolina School of Medicine, Washington University St. Louis, Wendy Abrams, Yang Teng, Yang Teng of Brigham and Women’s Hospital
| No comments
Posted by Site Administrator on October 22, 2012
“With the transplantation of these neural stem cells, we are exploring a paradigm shift in the treatment of ALS. We have demonstrated that intraspinal transplantation is feasible and well-tolerated…”
Categories: Research News, Treatments
| Tags: A. Alfred Taubman Medical Research, ALS research, ALS treatments, American Neurological Association', amyotrophic lateral sclerosis, Bob Stehlin, Eva Feldman MD, Food and Drug Administration, intraspinal transplantation, Karl Johe, Lou Gehrig's disease, Neuralstem, NSI-566 spinal cord stem cells, PhD, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, University of Michigan Health System
| No comments
Posted by Site Administrator on October 19, 2012
Studies have shown patients who are “paced” live about 15 months longer than patients who don’t have the pacer, she said. And their lives are about nine months longer than patients who only have noninvasive ventilators.
Categories: Research News, Technology
| Tags: ALS, ALS community, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Christopher Reeve, diaphragm pacer, Dr. Behrooz Shabahang, Dr. Daniel Borreson, Dr. Deborah Gelinas, Dr. Raymond Onders, Food and Drug Administration, Hauenstein Neuroscience Center., Julia Bauer, laparoscopic surgery, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Saint Mary’s Health Care, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| No comments
